Effect of the compound GIZH -290 and levetiracetam on epileptic activity in rat brain structures on EEG models of bemegrid-induced seizures
Open Access
- 25 June 2021
- journal article
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 14-18
- https://doi.org/10.37489/2587-7836-2020-4-14-18
Abstract
The effect of levetiracetam (a derivative of 4-phenylpyrrolidone) and its original analog, the compound GIZH-290, on primary generalized epileptic activity (EpA) in rat brain structures (sensorimotor cortex, dorsal hippocampus-CA3 field and lateral hypothalamus field) on EEG models of bemegridinduced seizures was studied. It was found that EpA, after the introduction of bemegrid, appears in 1–2 minutes in the form of prolonged generalized high-amplitude discharges and is registered within 3 hours. GIZH-290 (5 mg/kg, intraperitoneal, 15 minutes after bemegrid) causes a significant (p < 0.05) decrease in the number of epileptic discharges in the cortex and at the level of the trend in the hippocampus, which is accompanied by a decrease in the amplitude of the Epi-discharges. Levetiracetam at a dose of 200 mg / kg does not significantly change the severity of paroxysmal activity (the number of convulsive discharges and their duration) caused by bemegrid.Keywords
This publication has 11 references indexed in Scilit:
- The role of glutamate and GABA receptors in the anticonvulsive effects of levetiracetam and a 4-phenylpirrolidone derivative (GIZh-290) in ratsNeurochemical Journal, 2017
- Сравнение противосудорожных и мнемотропных свойств новых производных 4-фенилпирролидона, леветирацетама и пирацетамаЭкспериментальная и клиническая фармакология, 2017
- Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondCNS Drugs, 2016
- Neurophysiology and Regulation of the Balance Between Excitation and Inhibition in Neocortical CircuitsBiological Psychiatry, 2016
- NEW BIOMOLECULAR TARGETS FOR ANTIEPILEPTIC DRUGSEpilepsy and paroxysmal conditions, 2015
- Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disordersPharmacology Biochemistry and Behavior, 2013
- Research advances in basic mechanisms of seizures and antiepileptic drug actionPharmacological Reports, 2013
- Mechanisms of Action of Antiepileptic DrugsInternational review of neurobiology, 2007
- SV2 modulates the size of the readily releasable pool of secretory vesiclesNature, 2001
- Antiabsence seizure activity of specific GABAB and γ-hydroxybutyric acid receptor antagonistsPharmacology Biochemistry and Behavior, 1996